All In Biotech

Drug Trial Radar · NCT06392009

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients With Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 10, 2024

Primary completion

Jun 2026

Study completion Jun 2028

Sponsor

Lead sponsor
GRIN Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study RAD-GRIN-201 is a phase 1B/2A trial to assess safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) type II. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A and one year in Part B/long-term treatment period. The treatment period in Part B may be extended based on a favorable benefit/risk profile.

Conditions

  • Tuberous Sclerosis Complex
  • Focal Cortical Dysplasia

Interventions

  • RadiprodilDrug

    Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), Adverse Drug Reactions (ADRs), TEAEs Leading to Discontinuation and Severity of TEAEsTime frame: from Baseline to End-of-study: 1 year 6 months
  2. Plasma concentration of radiprodil and maximum plasma concentration (Cmax)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
  3. Plasma concentration of radiprodil versus time, area under the curve (AUCt)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
  4. Pharmacokinetic plasma concentration of radiprodil: half-life (T1/2)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
  5. Pharmacokinetic plasma concentration of radiprodil: time to Cmax (Tmax)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
  6. Pharmacokinetic plasma concentration of radiprodil, clearance (Cl)Time frame: Titration Visit 1 (week 7): Pre-dose to 12 hours post-dose. Titration Visits 2,3,4 (week 8 to 13) and Maintenance Visit 7 (week 25): pre-dose to 5 hours post-dose
  7. Number of participants with abnormal laboratory tests resultsTime frame: from Baseline to End-of-study: 1 year 6 months
  8. Number of participants with abnormal physical and neurological examination findingsTime frame: Baseline, MV7, and in Part B: Month 3, 6, 9, 12: week 6, week 28, week 40, week 52, week 64, week 76
  9. Clinically relevant changes in safety parameters: systolic blood pressureTime frame: from Baseline to End-of-study: 1 year 6 months
  10. Clinically relevant changes in safety parameters: diastolic blood pressureTime frame: from Baseline to End-of-study: 1 year 6 months
  11. Clinically relevant changes in safety parameters: pulse rateTime frame: from Baseline to End-of-study: 1 year 6 months
  12. 12-Lead ECG: Mean change from Baseline to End-of-Treatment in RR intervalTime frame: from Baseline to End-of-study: 1 year 6 months
  13. 12-Lead ECG: Mean change from Baseline to End-of-Treatment in PR intervalTime frame: from Baseline to End-of-study: 1 year 6 months
  14. 12-Lead ECG: Mean change from Baseline to End-of-Treatment in QRS intervalTime frame: from Baseline to End-of-study: 1 year 6 months
  15. 12-Lead ECG: Mean change from Baseline to End-of-Treatment in QT intervalTime frame: from Baseline to End-of-study: 1 year 6 months
  16. 12-Lead ECG: Mean change from Baseline to End-of-Treatment in QTcF intervalTime frame: from Baseline to End-of-study: 1 year 6 months

Locations

18 sites in 8 countries. Site status is shown where the registry gives one.

  • Queensland Children Hospital

    South Brisbane, Australia

  • University Hospitals Leuven, Pediatric Neurology

    Leuven, Belgium

  • Alberta Children's Hospital

    Calgary, Canada

  • The Hospital for Sick Children (Sick Kids)

    Toronto, Canada

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)

    Roma, Italy

  • Universita Cattolica del Sacro Cuore - Policlinico Universitario "Agostino Gemelli"

    Roma, Italy

  • IRCCS Istituto Giannina Gaslini

    Genoa, Liguria, Italy

  • AOU Meyer

    Florence, Tuscany, Italy

  • UMC Uthrecht - Wilhelmina Kinderziekenhuis

    Utrecht, Netherlands

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Centrum Medyczne Plejady

    Krakow, Poland

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Poznan, Poland

  • Instytut Pomnik - Centrum Zdrowia Dziecka

    Warsaw, Poland

  • Hospital Universitario Vall D´Hebrón

    Barcelona, Spain

  • Hospital Materno Infantil Sant Joan de Deu de Barcelona

    Barcelona, Spain

  • Hospital Universitario Vithas La Milagrosa

    Madrid, Spain

  • Hospital Ruber Internacional

    Madrid, Spain

  • University Hospitals Bristol and Weston NHS Foundation Trust Bristol Royal Hospital for Children

    Bristol, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.